Paper38176263
RNA four-way junction (4WJ) for spontaneous cancer-targeting, effective tumor-regression, metastasis suppression, fast renal excretion and undetectable toxicity.
Li X and 10 others. Biomaterials, 2024. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. RNA four-way junction (4WJ) for spontaneous cancer-targeting, effective tumor-regression, metastasis suppression, fast renal excretion and undetectable toxicity. Papers, record 38176263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38176263
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- RNA four-way junction (4WJ) for spontaneous cancer-targeting, effective tumor-regression, metastasis suppression, fast renal excretion and undetectable toxicity.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Lung Neoplasms | Major topic |
| Nanoparticles | Major topic |
| Humans | |
| RNA | |
| Renal Elimination | |
| Drug Delivery Systems | |
| Cell Line, Tumor |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016058 | NCI NIH HHS | United States | P30CA016058 | PubMed and NIH | NIH RePORTER |
| R01 EY031452 | NEI NIH HHS | United States | R01EY031452 | PubMed and NIH | NIH RePORTER |
| U01 CA207946 | NCI NIH HHS | United States | U01CA207946 | PubMed and NIH | NIH RePORTER |
References110
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32507912 | Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? | Cancer Metastasis Rev | 2020 | https://conductscience.org/library/papers/32507912 | PubMed |
| 2 | 31955577 | Retained Stability of the RNA Structure in DNA Packaging Motor with a Single Mg2+ Ion Bound at the Double Mg-Clamp Structure. | J Phys Chem B | 2020 | https://conductscience.org/library/papers/31955577 | PubMed |
| 3 | 27125502 | Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology. | Mol Ther | 2016 | https://conductscience.org/library/papers/27125502 | PubMed |
| 4 | 29421609 | Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles. | J Control Release | 2018 | https://conductscience.org/library/papers/29421609 | PubMed |
| 5 | 11842187 | RNA hairpin-folding kinetics. | Proc Natl Acad Sci U S A | 2002 | https://conductscience.org/library/papers/11842187 | PubMed |
| 6 | 29051199 | Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2'-F RNA, and LNA in the context of Phi29 pRNA 3WJ. | RNA | 2018 | https://conductscience.org/library/papers/29051199 | PubMed |
| 7 | 35037525 | Utilizing RNA nanotechnology to construct negatively charged and ultrasound-responsive nanodroplets for targeted delivery of siRNA. | Drug Deliv | 2022 | https://conductscience.org/library/papers/35037525 | PubMed |
| 8 | 21102465 | The emerging field of RNA nanotechnology. | Nat Nanotechnol | 2010 | https://conductscience.org/library/papers/21102465 | PubMed |
| 9 | 33405070 | Lumasiran: First Approval. | Drugs | 2021 | https://conductscience.org/library/papers/33405070 | PubMed |
| 10 | 33277608 | Engineering precision nanoparticles for drug delivery. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33277608 | PubMed |
| 11 | 25770994 | Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. | Biomaterials | 2015 | https://conductscience.org/library/papers/25770994 | PubMed |
| 12 | 11139616 | TectoRNA: modular assembly units for the construction of RNA nano-objects. | Nucleic Acids Res | 2001 | https://conductscience.org/library/papers/11139616 | PubMed |
| 13 | 25652125 | Delivery of RNA nanoparticles into colorectal cancer metastases following systemic administration. | ACS Nano | 2015 | https://conductscience.org/library/papers/25652125 | PubMed |
| 14 | 29802763 | An RNA Origami Octahedron with Intrinsic siRNAs for Potent Gene Knockdown. | Biotechnol J | 2019 | https://conductscience.org/library/papers/29802763 | PubMed |
| 15 | 24823486 | Activation of c-Met and upregulation of CD44 expression are associated with the metastatic phenotype in the colorectal cancer liver metastasis model. | PLoS One | 2014 | https://conductscience.org/library/papers/24823486 | PubMed |
| 16 | 21229999 | Self-assembling RNA nanorings based on RNAI/II inverse kissing complexes. | Nano Lett | 2011 | https://conductscience.org/library/papers/21229999 | PubMed |
| 17 | 34677049 | The International Society of RNA Nanotechnology and Nanomedicine (ISRNN): The Present and Future of the Burgeoning Field. | ACS Nano | 2021 | https://conductscience.org/library/papers/34677049 | PubMed |
| 18 | 31085078 | Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133. | Mol Ther | 2019 | https://conductscience.org/library/papers/31085078 | PubMed |
| 19 | 18935976 | RNA folding and ribosome assembly. | Curr Opin Chem Biol | 2008 | https://conductscience.org/library/papers/18935976 | PubMed |
| 20 | 32902260 | RNA Nanoparticles as Rubber for Compelling Vessel Extravasation to Enhance Tumor Targeting and for Fast Renal Excretion to Reduce Toxicity. | ACS Nano | 2020 | https://conductscience.org/library/papers/32902260 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42217082 | Pan-cancer multi-omics analysis identifies SYNGR4 as a novel clinical prognostic biomarker and therapeutic target in lung adenocarcinoma. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42217082 | PubMed |
| 42006041 | RNA-Micelles as Self-Assembling Structures for Efficient Co-Delivery of Synergistic siRNA and Nucleoside Analogues to Treat CRC Lung Metastasis. | Adv Funct Mater | 2026 | https://conductscience.org/library/papers/42006041 | PubMed |
| 41640711 | Nucleic Acid Nanoparticles Redefine Traditional Regulatory Terminology: The Blurred Line between Active Pharmaceutical Ingredients and Excipients. | ACS Nano Med | 2025 | https://conductscience.org/library/papers/41640711 | PubMed |
| 41634148 | Conjugation of hydrophobic drugs to motile pRNA 4WJ nanoparticles for spontaneous tumor targeting and undetectable toxicity. | Nat Protoc | 2026 | https://conductscience.org/library/papers/41634148 | PubMed |
| 41104418 | RNA Nanoparticles Harboring Radioisotopes or Other Imaging Molecules for Spontaneous Tumor Targeting for Early Cancer Diagnosis. | RNA Nanomed | 2025 | https://conductscience.org/library/papers/41104418 | PubMed |
| 40921731 | Developing Potent Therapeutics for Liver Cancer Chemoresistance via an RNA Nanotech and Series-Circuit-Christmas-Bulb Mechanism Targeting ABC Transporters. | Mol Pharm | 2026 | https://conductscience.org/library/papers/40921731 | PubMed |
| 40831543 | Leveraging Immunological Properties of Nucleic Acid Nanoparticles to Improve Cancer Therapy. | RNA Nanomed | 2025 | https://conductscience.org/library/papers/40831543 | PubMed |
| 40196906 | Synergistic RNA particles for spontaneous and specific cancer targeting but low toxicity due to motility and deformation. | Nanomedicine (Lond) | 2025 | https://conductscience.org/library/papers/40196906 | PubMed |
| 40193705 | DNA/RNA hybrids avoid channel gating that leads to the continued packaging of numerous hybrids into the phi29 protein shell. | Nucleic Acids Res | 2025 | https://conductscience.org/library/papers/40193705 | PubMed |
| 40131145 | Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials. | Mol Pharm | 2025 | https://conductscience.org/library/papers/40131145 | PubMed |
| 40125244 | Conversion of Chemical Drugs into Targeting Ligands on RNA Nanoparticles and Assessing Payload Stoichiometry for Optimal Biodistribution in Cancer Treatment. | RNA Nanomed | 2024 | https://conductscience.org/library/papers/40125244 | PubMed |
| 40125243 | Targeted Delivery of Potent Chemical Drugs and RNAi to Drug-Resistant Breast Cancer Using RNA-Nanotechnology and RNA-Ligand Displaying Extracellular vesicles. | RNA Nanomed | 2024 | https://conductscience.org/library/papers/40125243 | PubMed |
| 40115434 | pH-responsive bond as a linker for the release of chemical drugs from RNA-drug complexes in endosome or lysosome. | RNA Nanomed | 2024 | https://conductscience.org/library/papers/40115434 | PubMed |
| 40045577 | Using aptamers for targeted delivery of RNA therapies. | Mol Ther | 2025 | https://conductscience.org/library/papers/40045577 | PubMed |
| 39978660 | RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases. | Pharmacol Res | 2025 | https://conductscience.org/library/papers/39978660 | PubMed |
| 39388598 | RNA Nanotechnology for Codelivering High-Payload Nucleoside Analogs to Cancer with a Synergetic Effect. | Mol Pharm | 2024 | https://conductscience.org/library/papers/39388598 | PubMed |
| 39369270 | Engineered extracellular vesicles for combinatorial TNBC therapy: SR-SIM-guided design achieves substantial drug dosage reduction. | Mol Ther | 2024 | https://conductscience.org/library/papers/39369270 | PubMed |
| 39263430 | Therapeutic applications of RNA nanostructures. | RSC Adv | 2024 | https://conductscience.org/library/papers/39263430 | PubMed |
| 38833534 | Cracking the Code: Enhancing Molecular Tools for Progress in Nanobiotechnology. | ACS Appl Bio Mater | 2024 | https://conductscience.org/library/papers/38833534 | PubMed |
| 38214504 | In Vitro and In Vivo Evaluation of the Pathology and Safety Aspects of Three- and Four-Way Junction RNA Nanoparticles. | Mol Pharm | 2024 | https://conductscience.org/library/papers/38214504 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38176263
GET https://conductscience.org/api/papers/v1/38176263/references?page=2